• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    MIMEDX to Participate in Upcoming Investor Conferences

    5/27/25 8:00:00 AM ET
    $MDXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDXG alert in real time by email

    MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences:

    Craig-Hallum 22nd Annual Institutional Investor Conference | Minneapolis, MN

    1:1 sessions: Wednesday, May 28, 2025

    Goldman Sachs 46th Annual Global Healthcare Conference | Miami, FL

    1:1 sessions: Wednesday, June 11, 2025

    Northland Capital Growth Conference | Virtual

    1:1 sessions: Wednesday, June 25, 2025

    Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum, Goldman Sachs or Northland representative.

    About MIMEDX

    MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company's vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

    Contact:

    Matt Notarianni

    Investor Relations

    470-304-7291

    [email protected]



    Primary Logo

    Get the next $MDXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDXG

    DatePrice TargetRatingAnalyst
    7/2/2024$11.00Overweight
    Cantor Fitzgerald
    3/7/2024$12.00Buy
    Lake Street
    10/27/2023$12.00Buy
    Craig Hallum
    10/13/2022$7.00Buy
    Mizuho
    9/14/2021$20.00 → $8.50Buy
    HC Wainwright & Co.
    7/26/2021$23.00Outperform
    Northland Capital
    More analyst ratings

    $MDXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Capper Joseph H bought $1,268,000 worth of shares (200,000 units at $6.34), increasing direct ownership by 61% to 529,530 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      5/5/25 10:06:51 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Doug Rice bought $35,786 worth of shares (5,000 units at $7.16), increasing direct ownership by 5% to 102,200 units (SEC Form 4)

      4 - MIMEDX GROUP, INC. (0001376339) (Issuer)

      11/22/23 5:01:18 PM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MIMEDX to Participate in Upcoming Investor Conferences

      MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22nd Annual Institutional Investor Conference | Minneapolis, MN1:1 sessions: Wednesday, May 28, 2025 Goldman Sachs 46th Annual Global Healthcare Conference | Miami, FL1:1 sessions: Wednesday, June 11, 2025 Northland Capital Growth Conference | Virtual1:1 sessions: Wednesday, June 25, 2025 Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum, Goldman Sachs or Northland representative. About MIMEDXMI

      5/27/25 8:00:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX to Present at the BofA Securities 2025 Healthcare Conference

      MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare Conference in Las Vegas, NV. Presentation Details: Tuesday, May 13, 20255:15 p.m. PDTWebcast Link Investors interested in meeting with senior management at this event may contact their Bank of America representative. About MIMEDXMIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wou

      5/6/25 8:00:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

      MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX® (Dehydrated Human Amnion Chorion Membrane, or DHACM) following Mohs surgery. The study has been published in the May 2025 issue of Journal of Drugs in Dermatology: "Placental allograft reconstruction of cutaneous wounds following Mohs surgery: a propensity score-matched comparative cost-effectiveness analysis." Mohs surgery is widely accepted as the gold standard for treating many types of skin cancer, including basal and squamous cell carcinomas, which are the most comm

      5/5/25 8:30:00 AM ET
      $MDXG
      Biotechnology: Pharmaceutical Preparations
      Health Care